Applauding, cheering and renewing
acquaintances were all part of Daviaon
Qub Weekend eariy this month. More
than 200 club members, spouses and
guests attended the annual event which
included talks giving an "Update on
Medical Progress" at Duke, a football
game, receptions hosted by Dr. and Mis.
V>^lliam G. Anlyan and Prendent and
Mcs. Terry Sanford, a pre-game
luncheon with Sanford and a closing
dinner. "The Davison Oub Weekend
provides an opportunity for us to say
thank you to these valued friends,"
according to R.C. (Bucky) Waters,
assistant to the vice president for health
affairs and executive director of the
Davison Club.
Duke's football team helped nuke the
%veekend a success by beating Navy
28-16.
Davison Oub
Weekend,
1977
Photos by
John Becton
Roundtable features congressmen, FDA commissioner
Two congressmen, one of Canada's
most respected scientists and the head of
the Food and Drug Administration are
among ten speakers scheduled during
this year's Roundtable on Science and
Public Affairs lecture series which begins
Wednesday.
The series, one of whose goals is better
public understanding of science and
technology, opens with a talk by Dr.
Betsy Ancker-Johnson on "U.S.
Technology Policy: Its Domestic
Aspects."
Her talk, and all other lectiu«s in the
series, will begin at 8:15 p.m. in Cross
Chemical Laboratory auditorium. There
is no admission charge.
Ancker-Johnson wa« assistant
H-a-l-o-p-e-r-i-d-o-l may spell 'relief
(Continued from page 1)
Maltbie> said haloperidol so far has
shown none of these disadvantages. Nor
are patients prone to take more of the
drug than is ordered, he said, because no
narcotic "high" is produced.
Muscle and joint stiffness, the primary
side effects of the drug, ilso may keep
patients from taking more of the
medication than physicians prescribe, he
said.
In the upcoming clinical trials, which
will involve 40 cancer patients
complaining of pain, 20 patients will be
given coded doses of haloperidol, while
20 others will be given coded doses of a
placebo. The placebo will be a substance
with no pain killing properties.
After two weeks, the groups will be
reversed so that the first 20 patients
receive the placebo and the rest are given
haloperidol.
The study wiH be "double-blind" in
that neither the researchers nor the
patients will know who got the active
drug until all the data have been
collected, Maltbie said. Traditional pain
relievers will be available for all
participants as needed.
At the conclusion of the experiments,
the physicians will compare the amount
of narcotic drugs individuals took for
pain with records of when haloperidol
and placebo were administered.
"We want to find out if haloperidol is
as good a pain reliever as we now think
it is," Maltbie said. "One unanswered
question is obvious — is the medication
in some way correcting a psychiatric
disturbance which is not clinically
apparent, and in this way, is it only
relieving psydwlogical pain?
"We have chosen to woric with cancer
patients in this study because there is
virtually no question that their physical
illness is the cause of their pain," he
added.
secretary of commerce for science and
technology during the Ford
administration, and currently is a
member of the scientific staff at Argonne
National Laboratory.
Other speakers and dates are:
Nov. 3, Rep. Ray Thornton (D-Ark.), "The
Congressional Dilemma — Promoting Free
Scientific Inquiry While Protecting the Public
Interest."
Nov. 9, Rep. Mike McCormack (D-Wash.),
"A Responsible Attitude Toward a National
Energy Policy."
Nov. 30, Dr. Richard C. Atkinson, "Science
and the Citizen." Atkinson is director of the
National Science Foundation.
Jan. 25, Dr. David A. Hambui^g, "Emerging
Directions in Health Science Policy." . He is
president of the National Institute of Medicine
of the National Academy of Sciences.
Feb. 1, Dr. Oratond M. Solandt, "The
Canadian Arctic — Oil, Gas and People."
Solandt is former chancellor of the University
of Toronto and currently chairman of the
Science Advisory Board in the Northwest
Territories.
March 1, Dr. Eleanor Sheldon, "Social
Indicators and Public Decision Making." She
is president of the Social Science Research
Council.
March 8, Dr. Donald Kennedy, "Current
Issues in Federal Food and Drug Policy." He is
commissioner of the Food and Drug
Administration, but unlike recent
predecessors, not a physician.
April 5, Sir William Hawthorne, "Energy
and Environment: Conflict or Compromise."
Hawthorne is Master of Churchill College at
Cambridge University and regarded as one of
Britain's most distinguished engineers.
April 11, Dr. Alice M. Rivlin, "Congress and
the Budget." She is director of the
Congressional Budget Office and described by
those who know her as "a clear thinker and
straight talker."